Bevacizumab gamma for treating wet age-related macular degeneration: a cost-comparison technology appraisal

Shepherd, Jonathan, Chinnery, Fay, Maund, Emma, Scott, David Alexander and Lord, Joanne (2024) Bevacizumab gamma for treating wet age-related macular degeneration: a cost-comparison technology appraisal Southampton Health Technology Assessments Centre 66pp.

Record type: Monograph (Project Report)

Abstract

This report is a critique of the company’s submission (CS) to NICE from Outlook Therapeutics on bevacizumab gamma (LytenavaTM) (ONS-5010) for treating neovascular (wet) age-related macular degeneration (nAMD). It identifies the strengths and weakness of the CS.

Text

bevacizumab-gamma-for-treating-wet-agerelated-macular-degeneration-pdf-2973528330868933 - Version of Record

Available under License Other.

Download (72kB)

Text

Bevacizumab EAG report - Other

Restricted to Repository staff only

Available under License Creative Commons Attribution.

Request a copy

More information

Published date: 4 December 2024

Related URLs:

Identifiers

Local EPrints ID: 505882

URI: http://eprints.soton.ac.uk/id/eprint/505882

PURE UUID: f49a5a55-0cec-4c85-8dbe-ae8ce447e974

ORCID for Jonathan Shepherd:

orcid.org/0000-0003-1682-4330

ORCID for Fay Chinnery:

orcid.org/0000-0002-8082-9016

ORCID for Emma Maund:

orcid.org/0000-0002-3998-6669

ORCID for David Alexander Scott:

orcid.org/0000-0001-6475-8046

ORCID for Joanne Lord:

orcid.org/0000-0003-1086-1624

Catalogue record

Date deposited: 22 Oct 2025 16:41

Last modified: 23 Oct 2025 02:02

Export record

Share this record

Share this on Facebook Share this on Twitter Share this on Weibo

Contributors

Author: Jonathan Shepherd

Author: Fay Chinnery

Author: Emma Maund

Author: David Alexander Scott

Author: Joanne Lord

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Library staff additional information